Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | RAD52 | P43351 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25754717 | 0.92 | HRH3 (0.40) | KDM4EPOLBHRH3SMN1; SMN2CYP1A2 | |
| SCHEMBL25754752 | 0.89 | SMN1; SMN2 (0.38) | KDM4EPOLBHRH3ALDH1A1SMN1; SMN2 | |
| SCHEMBL25754697 | 0.88 | RAD52 (0.40) | KDM4EHRH3ALDH1A1SMN1; SMN2CYP1A2 | |
| SCHEMBL25754754 | 0.84 | KMT2A (0.36) | KDM4EPOLBHRH3ALDH1A1SMN1; SMN2 | |
| SCHEMBL25754725 | 0.82 | KMT2A (0.36) | KDM4EPOLBHRH3ALDH1A1SMN1; SMN2 | |
| SCHEMBL25754594 | 0.81 | CYP1A2 (0.42) | KDM4EPOLBHRH3ALDH1A1SMN1; SMN2 | |
| SCHEMBL25754758 | 0.81 | HRH3 (0.39) | KDM4EPOLBHRH3SMN1; SMN2CYP1A2 | |
| SCHEMBL25754739 | 0.80 | HRH2 (0.35) | KDM4EPOLB | |
| SCHEMBL25754613 | 0.77 | HRH3 (0.42) | HRH3ALDH1A1SMN1; SMN2CYP1A2MAPK1 | |
| SCHEMBL25754341 | 0.76 | KDM4E (0.42) | KDM4EPOLBALDH1A1SMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230210999-A1 | TARGETED PROTEASE DEGRADATION (TED) PLATFORM | EUBULUS BIOTHERAPEUTICS (HONG KONG) LIMITED (HK) | 2023-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230210999-A1 | TARGETED PROTEASE DEGRADATION (TED) PLATFORM | UCHL3, UBE2L3, ADAM33 | KDM4E 2658/4885POLB 4028/4885HRH3 1596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.